Mega Genomics

Mega Genomics Debt

The Debt of Mega Genomics (6667.HK) as of Nov 19, 2026 is 34.26 M CNY. In the previous year, Debt was 37.80 M CNY — a change of -9.37% (lower).

Debt

34.26 MCNY

YoY

-9.37%

Last updated:

In 2025, Mega Genomics's total debt was 34.26 M CNY, a -9.37% change from the 37.80 M CNY total debt recorded in the previous year.

The Mega Genomics Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2019
36.90 M CNY
Jan 1, 2020
22.80 M CNY
Jan 1, 2021
11.60 M CNY
Jan 1, 2022
10.99 M CNY
Jan 1, 2023
48.56 M CNY
Jan 1, 2024
37.80 M CNY
Jan 1, 2025
34.26 M CNY
The Mega Genomics Debt history
YEARDebtYoY
34.26 MCNY-9.37%
37.80 MCNY-22.16%
48.56 MCNY+342.04%
10.99 MCNY-5.29%
11.60 MCNY-49.12%
22.80 MCNY-38.21%
36.90 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mega Genomics Stock analysis

What does Mega Genomics do? Mega Genomics Ltd. generates revenue through three business segments. The Consumer Genetic Testing Services segment offers nutrition and metabolism testing, cancer risk assessment, chronic disease susceptibility analysis, pharmacogenetic testing, and infectious disease testing to individual consumers. The Cancer Screening Services segment provides specific tests including Septin9 for colorectal cancer, Syndecan-2 (SDC2) for colorectal cancer, and ring finger protein 180 (RNF180)/Septin9 for gastric cancer screening. The Other Services segment delivers genetic research and analysis services to third-party research institutions, creating additional revenue streams from institutional partnerships. The primary buyers for Consumer Genetic Testing Services are individual consumers seeking personalized health insights. Cancer Screening Services are utilized by healthcare providers and patients for early detection of colorectal and gastric cancers. Third-party research institutions purchase genetic research and analysis services from the Other Services segment to support their scientific studies and development projects. Mega Genomics Ltd. serves distinct market segments: individual consumers for genetic testing, healthcare providers for cancer screening, and research institutions for specialized genetic analysis. The company's revenue model relies on direct consumer sales, healthcare provider contracts, and institutional research partnerships to sustain its operations and growth. Mega Genomics is one of the most popular companies on Eulerpool.

Debt Details

Understanding Mega Genomics's Debt Structure

Mega Genomics's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Mega Genomics's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Mega Genomics’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Mega Genomics’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Mega Genomics stock

Debt of Mega Genomics is 34.26 M CNY in 2025.

Debt of Mega Genomics changed from 37.80 M CNY to 34.26 M CNY, representing a -9.37% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Mega Genomics since 2006 – with annual values, charts, and detailed analysis.

Debt's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Mega Genomics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Mega Genomics

All Key Metrics — Mega Genomics